Zeltiq Aesthetics Inc. (NASDAQ:ZLTQ)’s share price was down 2.9% during mid-day trading on Friday following insider selling activity. The company traded as low as $39.22 and last traded at $39.66, with a volume of 590,564 shares traded. The stock had previously closed at $40.83.
Specifically, Director Andrew N. Schiff sold 500,000 shares of Zeltiq Aesthetics stock in a transaction dated Thursday, August 11th. The stock was sold at an average price of $36.39, for a total value of $18,195,000.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mark J. Foley sold 10,000 shares of Zeltiq Aesthetics stock in a transaction dated Thursday, October 13th. The stock was sold at an average price of $40.55, for a total value of $405,500.00. Following the completion of the sale, the insider now owns 281,941 shares of the company’s stock, valued at $11,432,707.55. The disclosure for this sale can be found here. 15.60% of the stock is owned by insiders.
Several equities research analysts recently commented on the company. Stifel Nicolaus lifted their price objective on Zeltiq Aesthetics from $38.00 to $52.00 and gave the stock a “buy” rating in a report on Wednesday, September 21st. Leerink Swann reiterated an “outperform” rating and issued a $48.00 price objective on shares of Zeltiq Aesthetics in a report on Thursday, August 25th. Zacks Investment Research upgraded Zeltiq Aesthetics from a “sell” rating to a “hold” rating in a report on Friday, August 12th. JPMorgan Chase & Co. reiterated a “hold” rating and issued a $35.00 price objective (up from $27.00) on shares of Zeltiq Aesthetics in a report on Tuesday, August 9th. Finally, Brean Capital set a $39.00 price objective on Zeltiq Aesthetics and gave the stock a “buy” rating in a report on Tuesday, August 9th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has given a strong buy rating to the company. The company has an average rating of “Buy” and an average price target of $39.89.
The stock’s 50-day moving average price is $39.20 and its 200 day moving average price is $32.39. The company has a market capitalization of $1.56 billion, a P/E ratio of 59.35 and a beta of 0.79.
Zeltiq Aesthetics (NASDAQ:ZLTQ) last released its quarterly earnings results on Monday, August 8th. The company reported ($0.12) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.07. Zeltiq Aesthetics had a net margin of 9.54% and a negative return on equity of 9.90%. The business earned $89.50 million during the quarter, compared to analysts’ expectations of $79.68 million. During the same quarter last year, the business posted $0.03 earnings per share. The company’s quarterly revenue was up 38.9% compared to the same quarter last year. Analysts predict that Zeltiq Aesthetics Inc. will post ($0.13) earnings per share for the current year.
A number of large investors have recently added to or reduced their stakes in the stock. PineBridge Investments L.P. boosted its stake in Zeltiq Aesthetics by 4.9% in the second quarter. PineBridge Investments L.P. now owns 4,103 shares of the company’s stock worth $112,000 after buying an additional 193 shares during the period. Teacher Retirement System of Texas boosted its stake in Zeltiq Aesthetics by 26.9% in the second quarter. Teacher Retirement System of Texas now owns 4,884 shares of the company’s stock worth $133,000 after buying an additional 1,036 shares during the period. Mason Street Advisors LLC acquired a new stake in Zeltiq Aesthetics during the second quarter worth approximately $173,000. Calamos Wealth Management LLC acquired a new stake in Zeltiq Aesthetics during the second quarter worth approximately $200,000. Finally, First Mercantile Trust Co. acquired a new stake in Zeltiq Aesthetics during the third quarter worth approximately $204,000.
About Zeltiq Aesthetics
ZELTIQ Aesthetics, Inc is a medical technology company. The Company focuses on developing and commercializing products utilizing its controlled-cooling technology platform. Its product, the CoolSculpting System, is designed to reduce stubborn fat bulges. It sell the CoolSculpting system primarily to dermatologists, plastic surgeons, aesthetic specialists, and obstetrics and gynecology physicians.
Receive News & Ratings for Zeltiq Aesthetics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zeltiq Aesthetics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.